n, or blood thinners may increase bleeding risk. Patients should consult with their doctor before stopping Cymbalta or changing the dose. If patients experience dizziness or fainting upon standing while taking Cymbalta, they should contact their doctor. This is likely to occur in the first week or when increasing the dose, but may occur at any time during treatment. Cymbalta can increase blood pressure. Healthcare providers should check patients' blood pressure prior to and while taking Cymbalta. Patients should tell their doctor if they experience headache, weakness, confusion, problems concentrating, memory problems, or feel unsteady while taking Cymbalta as this may be signs of low sodium levels. Patients should consult their doctor if they develop problems with urine flow while taking Cymbalta. Female patients should tell their doctor if they are pregnant or plan to become pregnant during therapy or are breastfeeding.
The most common side effects of Cymbalta include nausea, dry mouth, sleepiness, fatigue, constipation, dizziness, decreased appetite, and increased sweating. This is not a complete list of side effects. Cymbalta may cause sleepiness and dizziness. Until patients know how Cymbalta affects them, they should not drive a car or operate hazardous machinery.
Take Cymbalta exactly as directed by your healthcare provider. Cymbalta should be taken by mouth. Do not open, break or chew capsule, it must be swallowed whole. Cymbalta can be taken with or without food.
For full Patient Information, visit http://www.cymbalta.com.
For full Prescribing Information, including Boxed Warning and Medication Guide, visit http://www.cymbalta.com.
DD PR ISI 4NOV10
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from Page: 1 2 3 4 5 Related medicine technology :1
. FDA Approves New Indication for Afinitor2
. FDA Approves Teflaro for Bacterial Infections3
. FDA Approves Latuda to Treat Schizophrenia in Adults4
. FDA Approves Additional Medical Indication for Sprycel5
. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation6
. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation7
. FDA Approves Botox to Treat Chronic Migraine8
. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients9
. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness10
. FDA Approves Combination Contraceptive Containing a Folate11
. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels